- Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
-
Lee J, Lee SH
- KMID: 2547638
- Korean J Intern Med.
- 2023 Nov;38(6):797-809.
- doi: 10.3904/kjim.2023.243
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD), and statins are the primary therapeutic options for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, it can be challenging... -
- CITED
-
- Close
- SHARE
-
- Close
- Lipid variability in patients with diabetes mellitus
-
Lee J, Lee SH
- KMID: 2547303
- Cardiovasc Prev Pharmacother.
- 2023 Oct;5(4):126-133.
- doi: 10.36011/cpp.2023.5.e18
Diabetic dyslipidemia is characterized by hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), elevated low-density lipoprotein cholesterol (LDL-C), and the predominance of small dense LDL particles caused by insulin resistance in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Diabetes and Dietary Fats
-
Cho JW
- KMID: 2546633
- J Korean Diabetes.
- 2023 Sep;24(3):154-163.
- doi: 10.4093/jkd.2023.24.3.154
Fats are important nutrients that supply energy and help to regulate the processes of the human body. The proportion of fat in the energy intake of Koreans, as well as... -
- CITED
-
- Close
- SHARE
-
- Close
- 2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors
-
Yang YS
- KMID: 2546630
- J Korean Diabetes.
- 2023 Sep;24(3):135-140.
- doi: 10.4093/jkd.2023.24.3.135
To prevent cardiovascular disease (CVD), which is one of the ultimate goals in the management of patients with diabetes, it is important to control not only hyperglycemia, but also modifiable... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Dyslipidemia in Patients with Diabetes Mellitus
-
Lee KA
- KMID: 2546627
- J Korean Diabetes.
- 2023 Sep;24(3):111-119.
- doi: 10.4093/jkd.2023.24.3.111
Most patients with diabetes mellitus (DM) have dyslipidemia, which is characterized by increased triglycerides, decreased high-density lipoprotein cholesterol, and increased small dense low-density lipoprotein cholesterol (LDL-C). Dyslipidemia is an important... -
- CITED
-
- Close
- SHARE
-
- Close
- Public Awareness of Dyslipidemia Among the Korean Population: A Survey Study
-
Bae JH, Jin ES, Kim SE, Kang S, Lee JY, Kim M, Jin HY, Shin MJ, Jeong IK, the Committee of Public Relation of the Korean Society of Lipid and Atherosclerosis
- KMID: 2546562
- J Lipid Atheroscler.
- 2023 Sep;12(3):307-314.
- doi: 10.12997/jla.2023.12.3.307
Objective: We aimed to assess the level of public awareness regarding dyslipidemia and its management among the Korean population. Methods: We conducted a web- or mobile-based survey study targeting the general... -
- CITED
-
- Close
- SHARE
-
- Close
- Dyslipidemia Fact Sheet in South Korea, 2022
-
Jin ES, Shim JS, Kim SE, Bae JH, Kang S, Won JC, Shin MJ, Jin HY, Moon J, Lee H, Kim HC, Jeong IK, on Behalf of the Committee of Public Relation of the Korean Society of Lipid and Atherosclerosis
- KMID: 2546122
- Diabetes Metab J.
- 2023 Sep;47(5):632-642.
- doi: 10.4093/dmj.2023.0135
Background: This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name... -
- CITED
-
- Close
- SHARE
-
- Close
- Dyslipidemia Fact Sheet in South Korea, 2022
-
Jin ES, Shim JS, Kim SE, Bae JH, Kang S, Won JC, Shin MJ, Jin HY, Moon J, Lee H, Kim HC, Jeong IK, on behalf of the Committee of Public Relation of the Korean Society of Lipid and Atherosclerosis
- KMID: 2546557
- J Lipid Atheroscler.
- 2023 Sep;12(3):237-251.
- doi: 10.12997/jla.2023.12.3.237
Objective: This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name... -
- CITED
-
- Close
- SHARE
-
- Close
- Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
-
Suh SH, Kim SW
- KMID: 2546120
- Diabetes Metab J.
- 2023 Sep;47(5):612-629.
- doi: 10.4093/dmj.2023.0067
Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney... -
- CITED
-
- Close
- SHARE
-
- Close
- The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma
-
Park SH, Lee YJ, Cheon JE, Shin CH, Jung HW, Lee YA
- KMID: 2543291
- Ann Pediatr Endocrinol Metab.
- 2023 Jun;28(2):107-115.
- doi: 10.6065/apem.2244046.023
Purpose: Hypothalamic damage may increase the risk of adulthood obesity and cardiovascular disease in patients with craniopharyngioma. We evaluated the effects of hypothalamic involvement (HI) and growth hormone (GH) discontinuation... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus
-
Moon MK, Noh J, Rhee EJ, Park SH, Kim HC, Kim BJ, Kim HJ, Choi S, Na JO, Hyun YY, Kim BJ, Han KD, Jeong IK, on Behalf of the Committee of Practice Guideline of Korean Lipid and Atheroscelerosis
- KMID: 2538930
- Diabetes Metab J.
- 2023 Jan;47(1):45-58.
- doi: 10.4093/dmj.2021.0344
Background: There are no clear data to support the cardiovascular (CV) risk categories and low-density lipoprotein cholesterol (LDL-C) treatment goals in Korean people with type 2 diabetes mellitus (T2DM). We... -
- CITED
-
- Close
- SHARE
-
- Close
- Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
-
Yang YS, Kim HL, Kim SH, Moon MK, on Behalf of Committee of Clinical Practice Guideline, Korean Diabetes Association and Clinical Practice Guideline Committee, Korean Society of Lipid and Atherosclerosis
- KMID: 2538926
- Diabetes Metab J.
- 2023 Jan;47(1):1-9.
- doi: 10.4093/dmj.2022.0448
Dyslipidemia in patients with diabetes is an important treatment target as a modifiable risk factor for cardiovascular disease (CVD). Although the primary treatment goal for dyslipidemia is to control low-density... -
- CITED
-
- Close
- SHARE
-
- Close
- Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
-
Yang YS, Kim HL, Kim SH, Moon MK, on behalf of Committee of Clinical Practice Guideline, Korean Diabetes Association and Clinical Practice Guideline Committee, Korean Society of Lipid and Atherosclerosis
- KMID: 2539210
- J Lipid Atheroscler.
- 2023 Jan;12(1):12-22.
- doi: 10.12997/jla.2023.12.1.12
Dyslipidemia in patients with diabetes is an important treatment target as a modifiable risk factor for cardiovascular disease (CVD). Although the primary treatment goal for dyslipidemia is to control low-density... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases
-
Shin HS, Jun BG, Yi SW
- KMID: 2534342
- Clin Mol Hepatol.
- 2022 Oct;28(4):773-789.
- doi: 10.3350/cmh.2021.0383
Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver diseases (CLDs) are not well understood. For... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of Dyslipidemia after Stroke
-
Chang Yk, Song TJ
- KMID: 2532117
- J Korean Neurol Assoc.
- 2022 Aug;40(3):217-227.
- doi: 10.17340/jkna.2022.3.1
Dyslipidemia is a major risk factor for stroke, following hypertension, diabetes, and smoking. Treatment of dyslipidemia is important for the prevention and treatment of various vascular diseases, including stroke, coronary... -
- CITED
-
- Close
- SHARE
-
- Close
- Screening and Management for Dyslipidemia in Korean Children and Adolescents
-
Yoon JS, Hwang IT
- KMID: 2532210
- Ewha Med J.
- 2022 Jul;45(3):e4.
- doi: 10.12771/emj.2022.e4
Cardiovascular disease (CVD) is the most common cause of death worldwide, and dyslipidemia is a major risk factor. Atherosclerosis can begin in childhood and continue into adulthood, thereby contributing to... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of the addition of thiazolidinedione to sodium-glucose cotransporter 2 inhibitor therapy on lipid levels in type 2 diabetes mellitus: a retrospective study using Korean National Health Insurance Service data
-
Park T, Han K, Shin D, Park J
- KMID: 2532277
- Cardiovasc Prev Pharmacother.
- 2022 Jul;4(3):114-122.
- doi: 10.36011/cpp.2022.4.e15
Background: Dyslipidemia is common in patients with type 2 diabetes mellitus (T2D) and contributes to an increased risk of cardiovascular disease. Previous studies have shown that treatment with thiazolidinediones (TZDs)... -
- CITED
-
- Close
- SHARE
-
- Close
- New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
-
Kim K, Ginsberg HN, Choi SH
- KMID: 2531956
- Diabetes Metab J.
- 2022 Jul;46(4):517-532.
- doi: 10.4093/dmj.2022.0198
Statins are the cornerstone of the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been... -
- CITED
-
- Close
- SHARE
-
- Close
- Atherogenic Index of Plasma Predicts Early Recurrent Ischemic Lesion in Acute Ischemic Stroke
-
Nam KW, Kwon HM, Lee YS
- KMID: 2534558
- J Neurosonol Neuroimag.
- 2022 Jun;14(1):42-50.
- doi: 10.31728/jnn.2022.00117
Background: Atherogenic index of plasma (AIP) is an index representing the lipid profile of atherogenic dyslipidemia and has been shown to be associated with various atherosclerosis, metabolic diseases, and cardiovascular... -
- CITED
-
- Close
- SHARE
-
- Close
- Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines
-
Yun SJ, Jeong IK, Cha JH, Lee J, Cho HC, Choi SH, Chun S, Jeon HJ, Kang HC, Kim SS, Ko SH, Koh G, Kwon SK, Lee JH, Moon MK, Noh J, Park CY, Kim S
- KMID: 2530185
- Diabetes Metab J.
- 2022 May;46(3):464-475.
- doi: 10.4093/dmj.2021.0088
Background: We evaluated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients with type 2 diabetes mellitus (T2DM) according to up-to-date Korean Diabetes Association (KDA), European Society of Cardiology... -
- CITED
-
- Close
- SHARE
-
- Close
